Recanalization following Endovascular treatment and imaging of PErfusion,Regional inFarction and atrophy to Understand Stroke Evolution

Abstract

Rationale

Following endovascular treatment, poor clinical outcomes are more frequent if the initial infarct core or volume of irreversible brain damage is large. Clinical outcomes may be improved using neuroprotective agents that reduce stroke volume and improve recovery.

Aim

The aim of the REPERFUSE NA1 was to replicate the preclinical neuroprotection study that significantly reduced infarct volume in a primate model of ischemia reperfusion. Specifically, REPERFUSE NA1 will determine if administration of the neuroprotectant NA1 prior to endovascular therapy can significantly reduce early (Day 2 subtract Day 1 diffusion-weighted imaging volume) and delayed secondary infarct (90-day whole brain atrophy plus FLAIR volume—Day 1 diffusion-weighted imaging volume) growth, as measured by magnetic resonance imaging.

Methods and design

REPERFUSE-NA1 is a magnetic resonance imaging observational substudy of ESCAPE-NA1 (ClinicalTrialGov NCT02930018). A total of 150 acute stroke patients will be recruited (including 20% attrition) that have been randomized to either NA1 or placebo in the ESCAPE-NA1 trial.

Study outcomes

Primary—Early infarct growth measured using diffusion-weighted imaging will be at least 30% smaller in patients receiving NA1 compared to placebo. Secondary—Delayed secondary stroke injury at 90 days will be significantly reduced in patients receiving NA1 compared to placebo, as well as delayed secondary growth at 90 days.

Conclusion

REPERFUSE-NA1 will demonstrate the effect of NA1 neuroprotection on reducing the early and delayed stroke injury after reperfusion treatment.

Keywords

Acute ischemic stroke reperfusion NA1 recanalization clinical trial brain imaging endovascular

Get full access to this article

View all access options for this article.

References

Roman

Menon

Blasco

, et al. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurol 2018; 17: 895–904.

Wahlgren

Ahmed

Eriksson

, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 2008; 39: 3316–3322.

Smith

Sung

Saver

, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39: 1205–1212.

Sah RG, d'Esterre CD, Hill MD, et al. Diffusion-weighted imaging lesion growth occurs despite recanalization in acute ischemic stroke: implications for future treatment trials. Int J Stroke 2018; 14: 257–264.

Cook

Teves

Tymianski

. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 2012; 483: 213–217.

Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. New England Journal of Medicine 2015; 372: 1019–1030.

Bruno

Saha

Williams

. Percent change on the National Institutes of Health Stroke Scale: a useful acute stroke outcome measure. J Stroke Cerebrovasc Dis 2009; 18: 56–59.

Broderick

Kothari

, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 2000; 31: 2335–2341.

d'Esterre

Boesen

Ahn

, et al. Time-dependent computed tomographic perfusion thresholds for patients with acute ischemic stroke. Stroke 2015; 46: 3390–3397.

10.

Warach

Gaa

Siewert

Wielopolski

Edelman

. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995; 37: 231–241.

11.

Barrett

Ding

Wagner

Kallmes

Johnston

. Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: results of the Acute Stroke Accurate Prediction (ASAP) trial serial imaging substudy. Stroke 2009; 40: 2422–2427.

12.

Beaulieu

de Crespigny

Tong

Moseley

Albers

Marks

. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome. Ann Neurol 1999; 46: 568–578.

13.

Kazemi

Silva

Fisher

Sotak

. Investigation of techniques to quantify in vivo lesion volume based on comparison of water apparent diffusion coefficient (ADC) maps with histology in focal cerebral ischemia of rats. Magn Reson Imaging 2004; 22: 653–659.

14.

Schaller

Graf

. Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab 2004; 24: 351–371.

15.

Ejaz S, Williamson DJ, Ahmed T, et al. Characterizing infarction and selective neuronal loss following temporary focal cerebral ischemia in the rat: a multi-modality imaging study. Neurobiol Dis 2012; 51: 120–132.

16.

Ejaz

Williamson

Ahmed

, et al. Characterizing infarction and selective neuronal loss following temporary focal cerebral ischemia in the rat: a multi-modality imaging study. Neurobiol Dis 2013; 51: 120–132.

17.

Gaudinski

Henning

Miracle

Luby

Warach

Latour

. Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant. Stroke 2008; 39: 2765–2768.

18.

Lovblad

Baird

Schlaug

, et al. Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome. Ann Neurol 1997; 42: 164–170.

19.

Bratane

Cui